- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Torkinib (PP242) 是一種選擇性的mTOR抑制劑,在無細胞試驗中IC50為8 nM;靶向作用于mTOR復合體,作用于mTOR比作用于PI3Kδ或PI3Kα/β/γ選擇性分別高10倍多和100倍。Torkinib (PP242) 可誘導線粒體自噬和凋亡。
Torkinib (PP242) Chemical Structure
CAS: 1092351-67-1
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HT-p21 | Function Assay | 50-1250 nM | 24 h | inhibits phosphorylation of S6 kinase (target of mTORC1) and its downstream target phospho-S6? | 26177051 |
U87vIII? | Function Assay | 0.04-2.5 μM | 24 h | inhibits mTORC1 and mTORC2 activities? | 26134617 |
U87vIII? | Function Assay | 2.5/5 μM | 12 h | inhibits gap closing in a dose-dependent manner | 26134617 |
3T3-L1 | Function Assay | 15 μM | 4 h | suppresses expression of the Egr1 protein? | 25814662 |
Rh30 | Function Assay | 1 μM | 2 h | inhibits both mTORC1-mediated phosphorylation of S6K1 and mTORC2-mediated phosphorylation of Akt | 25762619 |
HT29 | Function Assay | 1 μM | 2 h | inhibits both mTORC1-mediated phosphorylation of S6K1 and mTORC2-mediated phosphorylation of Akt | 25762619 |
Rh30 | Function Assay | 1 μM | 2 h | suppresses the basal or IGF-1-stimulated cell adhesion | 25762619 |
HT29 | Function Assay | 1 μM | 2 h | suppresses the basal or IGF-1-stimulated cell adhesion | 25762619 |
U87 | Growth Inhibition Assay | 25 nM | 24 h | increases DUSP10 knocked-down induced cell inhibition | 25568665 |
AGS | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
MKN45 | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
MKN28 | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
KATO3 | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
SGC7901 | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
N87 | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
HMEC | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
HUVEC | Cell Viability Assay | 0-1000 nM | 24/48 h | decreases cell viability in time and dose dependent manner | 25035961 |
MG63 | Function Assay | 50-1000 nM | 0.5 h | dose dependently (50–1000 nM) inhibits phosphorylation of Akt | 24840134 |
U2OS? | Function Assay | 50-1000 nM | 0.5 h | dose dependently (50–1000 nM) inhibits phosphorylation of Akt | 24840134 |
Saos-2? | Function Assay | 50-1000 nM | 0.5 h | dose dependently (50–1000 nM) inhibits phosphorylation of Akt | 24840134 |
Saos-2 | Function Assay | 100 nM | 0.5 h | prevents osteosarcoma cell migration | 24840134 |
MG63 | Apoptosis Assay | 100 nM | 36 h | promotes apoptosis | 24840134 |
U2OS? | Apoptosis Assay | 100 nM | 36 h | promotes apoptosis | 24840134 |
Saos-2? | Apoptosis Assay | 100 nM | 36 h | promotes apoptosis | 24840134 |
DLD-1 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Caco2 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
HT29 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
H116 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Hct-8 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Colo320 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Sw948 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Colo205 | Cell Viability Assay | 0-1000 nM | 24 h | inhibits the growth in a dose-dependent manner | 23991179 |
Colo320 | Function Assay | 1 μM | 0-24 h | abolishes the S6S235/236?but partially reduces the 4E-BP1T36/45 | 23991179 |
HT29 | Function Assay | 1 μM | 0-24 h | abolishes the S6S235/236?but partially reduces the 4E-BP1T36/45 | 23991179 |
Sw948 | Function Assay | 1 μM | 0-24 h | abolishes the S6S235/236?but partially reduces the 4E-BP1T36/45 | 23991179 |
DLD-1 | Function Assay | 1 μM | 0-24 h | abolishes the S6S235/236?but partially reduces the 4E-BP1T36/45 | 23991179 |
786-O | Function Assay | 0.1/0.5 μM | 24 h | increases E-cadherin mRNA levels dose dependently | 23147251 |
786-O | Function Assay | 0-0.5 μM | 24 h | results in a dose dependent increase in E-cadherin protein expression? | 23147251 |
OCI-AML3 | Apoptosis Assay | 2.5 μM | 72 h | induces apoptosis | 22826565 |
Jurkat | Function Assay | 100/200/400 nM | 18 h | inhibits mTORC1-dependent S6 S235/236 phosphorylation | 22566604 |
p210 BCR-Abl | Function Assay | 100/200/400 nM | 18 h | inhibits mTORC1-dependent S6 S235/236 phosphorylation | 22566604 |
Jurkat | Growth Inhibition Assay | 400nM | 24/48 h | synergize with 17-AAG to suppress cell proliferation | 22566604 |
p210 BCR-Abl | Growth Inhibition Assay | 400nM | 24/48 h | synergize with 17-AAG to suppress cell proliferation | 22566604 |
8226 | Function Assay | 100-1000 nM | 30 min | activates ERK? | 22556409 |
MM1.S? | Function Assay | 100-1000 nM | 30 min | activates ERK? | 22556409 |
8226 | Function Assay | 0.5 μM | 30 min | induces activation of RAF and phosphorylation of MEK | 22556409 |
MM1.S? | Function Assay | 0.5 μM | 30 min | induces activation of RAF and phosphorylation of MEK | 22556409 |
MCF-7 | Function Assay | 50/200/500 nM | 30 min | dose-dependently (50–500?nM) suppresses phosphorylation of Akt | 22476852 |
T47D | Function Assay | 50/200/500 nM | 30 min | dose-dependently (50–500?nM) suppresses phosphorylation of Akt | 22476852 |
MDA-MB-231 | Function Assay | 50/200/500 nM | 30 min | dose-dependently (50–500?nM) suppresses phosphorylation of Akt | 22476852 |
Bcap-37 | Function Assay | 50/200/500 nM | 30 min | dose-dependently (50–500?nM) suppresses phosphorylation of Akt | 22476852 |
MCF-7 | Apoptosis Assay | 200?nM | 36 h | induces apoptosis | 22476852 |
MDA-MB-231 | Apoptosis Assay | 200?nM | 36 h | induces apoptosis | 22476852 |
Bcap-37 | Apoptosis Assay | 200?nM | 36 h | induces apoptosis | 22476852 |
LS174T | Function Assay | 10/100/1000 nM | 6 h | inhibits mTORC1 activity by the dephosphorylation of S6 ribosomal protein | 22401294 |
DLD-1? | Function Assay | 10/100/1000 nM | 6 h | inhibits mTORC1 activity by the dephosphorylation of S6 ribosomal protein | 22401294 |
SW480 | Function Assay | 10/100/1000 nM | 6 h | inhibits mTORC1 activity by the dephosphorylation of S6 ribosomal protein | 22401294 |
NIH 3T3 | Function Assay | 2 μM | 18 h | inhibits mTORC2 phosphorylation of Akt on Ser473 and mTORC1 phosphorylation of 4E-BP1 on Thr37/46 | 21876130 |
HCT15 | Function Assay | 0.5/2 μM | 4 h | prevents S6K1 phosphorylation of ribosomal protein S6 at Ser240/244 and mTORC2 phosphorylation of Akt at Ser473 | 21876130 |
SW620? | Function Assay | 0.5/2 μM | 4 h | blocks all three mTOR outputs | 21876130 |
PC12? | Function Assay | 40?nM | induces lysosomal biogenesis and alleviated α-SYN accumulation? | 26001614 | |
DND-1 | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
TMD8 | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
Jurkat | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
KOPT-K1 | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
TMD7 | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
THP-1 | Growth Inhibition Assay | 0.25/0.5/1 μM | inhibits cell growth dose dependently | 23482748 | |
HT1376 | Growth Inhibition Assay | IC50=1.88 ± 1.1 μM | 24054871 | ||
T24 | Growth Inhibition Assay | IC50=1.37 ± 0.4 μM | 24054871 | ||
UM-UC-3 | Growth Inhibition Assay | IC50=0.63 ±0.1 μM | 24054871 | ||
SW620 | Growth Inhibition Assay | IC50=7.8 μM | 23542178 | ||
SW480 | Growth Inhibition Assay | IC50=4.6 μM | 23542178 | ||
SK-CO-1 | Growth Inhibition Assay | IC50=4 μM | 23542178 | ||
LS-513 | Growth Inhibition Assay | IC50=3.9 μM | 23542178 | ||
SW1116 | Growth Inhibition Assay | IC50=0.84 μM | 23542178 | ||
LS-174T | Growth Inhibition Assay | IC50=0.84 μM | 23542178 | ||
HCT 116 | Growth Inhibition Assay | IC50=0.41 μM | 23542178 | ||
HCT 15 | Growth Inhibition Assay | IC50=0.3 μM | 23542178 | ||
COLO 205 | Growth Inhibition Assay | IC50=0.24 μM | 23542178 | ||
HT-29 | Growth Inhibition Assay | IC50=0.23 μM | 23542178 | ||
COLO 201 | Growth Inhibition Assay | IC50=0.23 μM | 23542178 | ||
Caco-2 | Growth Inhibition Assay | IC50=0.22 μM | 23542178 | ||
SW48 | Growth Inhibition Assay | IC50=0.09 μM | 23542178 | ||
SW-48 | Growth Inhibition Assay | IC50=0.1 μM | 22270257 | ||
HCT-15 | Growth Inhibition Assay | IC50=0.3 μM | 22270257 | ||
HCT 116 | Growth Inhibition Assay | IC50=0.6 μM | 22270257 | ||
SW620-R | Growth Inhibition Assay | IC50=1.3 μM | 22270257 | ||
SK-CO-1 | Growth Inhibition Assay | IC50=2.1 μM | 22270257 | ||
SW620 | Growth Inhibition Assay | IC50=11 μM | 22270257 | ||
BaF3 | Growth Inhibition Assay | GI50=1.449 μM | 22223645 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Torkinib (PP242) 是一種選擇性的mTOR抑制劑,在無細胞試驗中IC50為8 nM;靶向作用于mTOR復合體,作用于mTOR比作用于PI3Kδ或PI3Kα/β/γ選擇性分別高10倍多和100倍。Torkinib (PP242) 可誘導線粒體自噬和凋亡。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
特性 | 第一批以mTOR的ATP域為靶點的選擇性抑制劑之一。 | ||||||||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | PP242作用于mTOR比作用于其他PI3K家族激酶,比如p110α,p110β,p110γ,p110δ,和DNA-PK(IC50分別為1.96 μM,2.2 μM,1.27 μM,0.102 μM,和0.408 μM),表現(xiàn)出更有效的選擇性。PP242對Ret,PKCα,PKCβ,和JAK2表現(xiàn)出一定的抑制活性,而對215種其他蛋白激酶具有顯著的選擇性。不同于rapamycin,PP242同時抑制mTORC1和 mTORC2。在BT549細胞中,PP242治療(0.04-10 μM)以劑量依賴的方式抑制Akt,mTOR底物p70S6K,和其下游靶點S6的磷酸化。[1] PP242有效抑制PKCα,IC50 為49 nM。低濃度PP242抑制Akt S473磷酸化,較高濃度部分抑制除S473-P 外的Akt T308-P。PP242作為比rapamycin更有效的mTORC1抑制劑,能夠抑制原代MEFs細胞的增殖,以及4EBP1在T36/45和S65上的磷酸化,比rapamycin更有效。通過比rapamycin引起更高水平的4EBP1 和eIF4E結合,PP242有效抑制cap依賴性翻譯,而 rapamycin無此作用。[2] PP242有效抑制p190轉化的小鼠BM,SUP-B15,和K562細胞增殖,GI50分別為12 nM,90 nM,和85 nM。PP242也會抑制固體腫瘤細胞系,如SKOV3,PC3,786-O,和U87的生長,GI50 分別為0.49 μM,0.19 μM,2.13 μM,和1.57 μM。[3] PP242能夠比rapamycin更有效地使多發(fā)性骨髓瘤(MM)細胞減少和凋亡。[4] | |||
---|---|---|---|---|
激酶實驗 | 體外mTOR (FRAP1)激酶試驗 | |||
重組mTOR與50-0.001 μM濃度范圍內連續(xù)2倍稀釋的PP242在試驗緩沖液中進行培養(yǎng),緩沖液包含50 mM HEPES,pH 7.5,1 mM EGTA,10 mM MgCl2,0.01% Tween,10 μM ATP (2.5 μCi of γ-32P-ATP),和3 μg/mL BSA。大鼠重組PHAS-1/4EBP1 (2 mg/mL)用作底物。通過在1 M NaCl/1%磷酸(大約6次,每次5-10分鐘)洗滌過的硝酸纖維素上點樣終止反應。將板片干燥,轉移的放射性通過磷光成像定量。IC50值使用Prism軟件包將數(shù)據(jù)擬合到S形劑量反應曲線進行計算。 | ||||
細胞實驗 | 細胞系 | MEFs | ||
濃度 | 在DMSO中溶解,終濃度為~10 μM | |||
孵育時間 | 72小時 | |||
方法 | 細胞用逐漸增加濃度的PP242在96孔板中處理72小時。處理72小時后,將10 μL 440 μM刃天青鈉鹽加入到每孔中,18小時后,每孔中的熒光強度使用頂端讀取的熒光板閱讀器在530 nm激發(fā)波長和590 nm發(fā)射波長下測量。 | |||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | p-mTOR / mTOR / p-AKT / AKT / p-S6 / S6 / p-4E-BP1 / 4E-BP-1 | 23991179 | ||
Growth inhibition assay | Cell viability | 23991179 |
體內研究(In Vivo) | ||
體內研究活性 | 在小鼠脂肪和肝臟中,PP242給藥能夠完全抑制Akt在S473和T308的磷酸化。PP242僅部分抑制骨骼肌中Akt磷酸化,并且對T308磷酸化的抑制比對S473更有效,盡管其能夠完全抑制4EBP1和S6的磷酸化。[2] PP242口服給藥有效延緩白血病在小鼠模型中的發(fā)病,并通過抑制與細胞大小損失相關的mTORC2和mTORC1活化,誘導白血病消退。[3] PP242治療有效抑制小鼠體內8226細胞的生長。[4] | |
---|---|---|
動物實驗 | Animal Models | 負荷小鼠p190轉染的會引發(fā)白血病的BM細胞的同源(Balbc/J)小鼠,和靜脈注射SUP-B15ffLuc細胞或人Ph+白血病細胞的雌性小鼠 |
Dosages | ~60 mg/kg/day | |
Administration | 口服強飼 |
分子量 | 308.34 | 分子式 | C16H16N6O |
CAS號 | 1092351-67-1 | SDF | Download Torkinib (PP242) SDF |
Smiles | CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 61 mg/mL ( (197.83 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 |
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
Do you have any suggestions about potential candidates for vehicles that we could use for in vivo studies?
回答:
S2218 in the recommended solvent (30% PEG400 + 0.5% Tween80 + 5% Propylene glycol) is a suspension, and this formulation is for oral gavage. For IV injection, this compound can be dissolved in 2% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5mg/ml as a clear solution.